F-FDG PET can effectively rule out conversion to dementia and the presence of CSF biomarker of neurodegeneration: a real-world data analysis.

Fiche publication

Date publication

août 2024

Journal

Alzheimer's research & therapy

Auteurs

Membres identifiés du Cancéropôle Est :
Pr THILLY Nathalie , Pr VERGER Antoine

Tous les auteurs :
Heyer S, Simon M, Doyen M, Mortada A, Roch V, Jeanbert E, Thilly N, Malaplate C, Kearney-Schwartz A, Jonveaux T, Bannay A, Verger A

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39135067

Résumé

Precisely defining the delay in onset of dementia is a particular challenge for early diagnosis. Brain [F] fluoro-2-deoxy-2-D-glucose (F-FDG) Positron Emission Tomography (PET) is a particularly interesting tool for the early diagnosis of neurodegenerative diseases, through the measurement of the cerebral glucose metabolic rate. There is currently a lack of longitudinal studies under real-life conditions, with sufficient patients, to accurately evaluate the predictive values of brain F-FDG PET scans. Here, we aimed to estimate the value of brain F-FDG PET for predicting the risk of dementia conversion and the risk of occurrence of a neurodegenerative pathology.